Process validation in pharma is a documented lifecycle approach for demonstrating that a manufacturing process can consistently deliver product meeting predetermined quality attributes. FDA describes three stages—Process Design, Process Qualification and Continued Process Verification (CPV)—while EU GMP Annex 15 requires a lifecycle approach to qualification and validation. In operational terms, firms should establish product and process understanding, qualify the facilities, utilities and equipment used, execute and evaluate scientifically justified process-performance qualification (PPQ), then use ongoing data to maintain the validated state.
Neither FDA’s process validation guidance nor EU GMP Annex 15 establishes “three PPQ batches” as a universal rule. The number of batches, sampling plan, acceptance criteria and study design should be justified by process knowledge, risk and the particular manufacturing situation. A repeatable programme is therefore not a fixed batch count: it is an evidence system linking development knowledge, commercial controls, quality oversight and continuing verification.
What process validation means in a lifecycle programme
FDA’s Process Validation: General Principles and Practices presents process validation as lifecycle-based. Its recommendations are guidance, not binding regulations, but they set out FDA’s current thinking on how process-validation evidence should be developed and maintained. EU GMP Annex 15 is the European Commission’s GMP annex on qualification and validation. It states that qualification and validation should be performed throughout the lifecycle of the product and process.
The practical objective is consistent across these sources: manufacturing knowledge and controls must be sufficient to provide a high degree of assurance that the process will consistently produce product of the intended quality. Validation is not completed simply because a protocol has been executed. The validated state is sustained through appropriate monitoring, review, deviation investigation, change control and requalification or revalidation where needed.
A validation programme should also sit within a planned site framework. The Validation Master Plan under Annex 15 explains how a VMP can organise validation policy, responsibilities, key systems and the programme’s overall strategy. This is GuideGxP implementation advice; the VMP itself is not a substitute for product- and process-specific scientific justification.
FDA lifecycle stages and practical Annex 15 alignment
The FDA model is a useful operating structure even where a site’s procedures use different names. Annex 15 similarly expects planned lifecycle activity, documented evidence and ongoing control. The table below compares the concepts at a practical level; it does not replace either source document or the applicable GMP requirements.
| Lifecycle focus | FDA framing | Practical Annex 15 alignment | Core evidence |
|---|---|---|---|
| Knowledge and control strategy | Stage 1: Process Design | Development activity and lifecycle validation planning | Process knowledge, defined operating parameters, quality attributes, risk assessments and control strategy |
| Readiness and performance | Stage 2: Process Qualification, including facility and equipment qualification and PPQ | Qualification of premises, utilities and equipment, followed by process validation | Approved protocols, qualification records, PPQ batch records, analytical results, deviations and conclusions |
| Routine assurance | Stage 3: Continued Process Verification | Ongoing verification during the product lifecycle | Trend data, periodic review, investigations, change assessments and actions |
Stage 1: Process Design
Process Design is where commercial manufacturing process knowledge is established. It should define how inputs, operating ranges, equipment, controls and process steps support intended product quality. A clear distinction is needed between development observations and the knowledge that is sufficiently mature to support the commercial control strategy.
For the validation team, the output is not merely a development report. It is a usable basis for PPQ: critical aspects to be challenged or monitored, parameter ranges, in-process controls, sampling locations, test methods, acceptance criteria and foreseeable sources of variation. Where scale-up, technology transfer or new equipment changes the manufacturing context, the rationale for applying prior knowledge should be explicit.
Stage 2: Process Qualification and PPQ
FDA Stage 2 has two elements. First, the manufacturing facility, utilities and equipment must be suitably qualified. Second, PPQ demonstrates that the process, as designed and controlled, can perform effectively and reproducibly in the intended manufacturing setting. Annex 15 likewise addresses qualification of premises, utilities and equipment and validation of the manufacturing process.
PPQ should be conducted under an approved protocol with predefined acceptance criteria and a justified sampling and testing plan. Routine commercial-scale manufacture is generally the relevant setting for the performance study, because the purpose is to establish evidence for the actual intended process. The protocol should identify the process, equipment train, materials, batch size or range where applicable, operating parameters, responsibilities, data handling, deviations and decision rules.
Sampling must be capable of assessing the process rather than simply accumulating results. Locations, timing and quantity should be justified in relation to process understanding, expected variability and the attributes being assessed. Statistical methods should be appropriate to the data and question. A statistical calculation cannot correct inadequate sampling, unclear acceptance criteria or an unrepresentative study design.
Stage 3: Continued Process Verification
CPV is the continuing collection and evaluation of process-performance data after PPQ. Its purpose is to detect whether the process remains in a state of control and to identify signals that require evaluation. It should be established before routine manufacture proceeds as the normal operating mode, with defined ownership between Manufacturing, QA, QC, Engineering and technical functions.
Useful CPV indicators arise from the approved control strategy and may include critical process parameters, in-process results, yield, quality attributes, analytical results, deviations, rejects, complaints and relevant equipment or utility performance. The appropriate indicators, frequencies, alerting approach and review cadence are product- and process-specific. Trend evaluation should lead to documented decisions, not passive dashboards.
How to design a defensible PPQ protocol
A PPQ protocol is an executable scientific plan, not a retrospective narrative. It should make it possible for an independent reviewer to understand what will be done, why that design is appropriate, how data will be assessed and what happens if the study does not proceed as planned.
- Scope and rationale: identify the product, process, site, equipment, intended commercial conditions and the scientific basis for the PPQ approach.
- Readiness: confirm that relevant facilities, utilities, equipment, methods and supporting systems are qualified or otherwise ready for intended use.
- Control strategy: specify the parameters, controls and quality attributes to be evaluated, including the approved operating ranges and acceptance criteria.
- Batch and sampling design: justify the number of PPQ batches and explain sampling locations, timing, quantities, tests and any increased sampling.
- Data evaluation: predefine the statistical or graphical methods, treatment of results and conclusions to be drawn from the evidence.
- Governance: define responsibilities, contemporaneous documentation, protocol amendments, deviation handling and approval of the final report.
Do not use a target batch number as a substitute for rationale. A small number of well-designed studies may still be insufficient if they fail to represent meaningful sources of variation; conversely, extra batches without a clear question do not automatically add persuasive evidence. The justification should be visible in the protocol and supported by process knowledge.
Inspection-ready PPQ and CPV checklist
The following is GuideGxP implementation advice derived from the lifecycle principles in the FDA guidance and Annex 15. It is a readiness aid, not an additional regulatory requirement.
- Is the validation approach approved, lifecycle-based and connected to the site validation plan?
- Can the team trace PPQ design decisions to process knowledge, risk assessment and the control strategy?
- Are premises, utilities, equipment and applicable methods ready for their intended use before PPQ execution?
- Does the protocol predefine batch rationale, sampling, tests, acceptance criteria, statistical evaluation and deviation governance?
- Are executed batch records, laboratory data, equipment records and protocol data complete, attributable and reviewable?
- Were deviations assessed for their effect on study validity, product quality and the PPQ conclusion rather than merely closed administratively?
- Does the report reconcile planned and actual work, address all departures and state a clear, approved conclusion?
- Is CPV defined with data sources, review frequency, escalation expectations, responsibilities and records of decisions?
- Are process changes evaluated through change control for their effect on the validated state and need for qualification, validation or enhanced monitoring?
- Can QA show how recurring trends, atypical outcomes and process signals are investigated and used to improve control?
Deviations, changes and common inspection pitfalls
A deviation during PPQ does not have a predetermined outcome. It requires a documented, scientifically sound assessment of its impact on the batch, the data set and the ability of the study to support its conclusion. Simply excluding inconvenient data, repeating a batch without justification or declaring a deviation unrelated without evidence weakens the study. The final report should transparently reconcile deviations, investigations, corrective actions where applicable and their effect on the validation conclusion.
Change control is equally central after PPQ. Changes to materials, suppliers, manufacturing steps, equipment, utilities, analytical methods, software or operating ranges may affect process performance. The change assessment should determine the required action based on impact and risk: for example, no additional validation activity, targeted qualification or verification, enhanced CPV, or revalidation. The decision and its rationale should be documented before implementation under the pharmaceutical quality system.
Frequent weaknesses include treating PPQ as a paperwork event; relying on an inherited “three-batch” convention without rationale; failing to connect sampling to process risk; using trends without defined action or escalation; and allowing development, qualification and commercial data to exist in disconnected systems. A mature programme makes the knowledge chain visible from process design through PPQ and ongoing verification.
FAQ
Is three-batch PPQ mandatory?
No universal three-batch requirement is stated in the supplied FDA guidance or EU GMP Annex 15 source. The PPQ number and design should be scientifically justified for the process and intended manufacturing circumstances.
Is PPQ the whole of process validation?
No. In FDA’s lifecycle model, PPQ is part of Stage 2, following Process Design and preceding Continued Process Verification. Annex 15 also takes a lifecycle approach.
When does CPV begin?
CPV is the ongoing verification stage following process qualification. Its monitoring approach should be defined so that routine manufacturing data are evaluated for continued process performance.
What should trigger revalidation?
There is no single automatic trigger presented here. Changes and emerging performance signals should be assessed through the quality system for their potential impact on the validated state and the appropriate additional activity.
Primary sources
- FDA: Process Validation: General Principles and Practices
- European Commission: EU GMP Annex 15 — Qualification and Validation
